Connect Biopharma Phase 3 atopic dermatitis study to be presented at AAD

March 10, 2026 9:00 AM

Connect Biopharma Holdings Limited (NASDAQ: CNTB) announced that results from a Phase 3 study of rademikibart in moderate-to-severe atopic dermatitis ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found